Abstract:Background: Tinea pedis is a dermatophytosis of the feet usually occurs between the toes with the webspace between the fourth and fifth digits but, in many cases, may appear as an extensive pattern on the bottom and sides of the feet. Terbinafine and itraconazole were evaluated with the efficacy/effectiveness and toxicity in the systemic treatment of Tinea pedis and compared with each other. Objective: To compare the efficacy and safety of terbinafine vs. itraconazole in treating tinea pedis. Materials and Methods: A total of 50 patients were selected, and they were divided into groups (group-A and group B), each of which included 25 patients. Group A was given oral Terbinafine 250 mg daily for two weeks. Group B was given oral Itraconazole 200mg daily for the same duration. Patients were observed for the efficacy and side effects of the trial medicines. A baseline complete blood picture, liver and renal function test, and urine analysis were done and repeated frequently during therapy. Results: Most patients were in the fourth decade in both groups, and the male-to-female ratio was almost 4:1. Two groups of people were studied: group-A with terbinafine 250 mg daily and group B with itraconazole 200 mg daily for 14 days. Evaluated weekly during treatment and 02 weeks after cessation of therapy, and finally on 08th week to see the clinical improvement and adverse effects. The clinical response was found in chronic hyperkeratotic type: 08/08, 08/08; chronic interdigital type: 07/07, 07/06; vesico-bullous type: 06/05, 06/05; Mixed type: 04/03, 03/02 in group-A and group-B respectively. On average, 92% clinical improvement was found in group-A and 84% in group B. Most patients had nausea (20.0%) followed by 08% diarrhea in group A. On the other hand, in group B, most patients had nausea (28.0%), followed by 4.0% fatigue and 4.0% diarrhea, and only 01 patient found elevated liver enzyme but did not exceed the upper limit. 80% of patients in the terbinafine group had transient, mild to moderate nausea. Conclusion: No significant differences in efficacy and toxicity were found between terbinafine and itraconazole groups. Terbinafine may represent a good alternative for treating Tinea Pedis in patients who cannot take itraconazole or other available drugs due to contraindications. TAJ 2022; 36: No-1: 75-82

Effectiveness and safety of oral terbinafine for dermatophyte distal subungual onychomycosis

Terbinafine versus itraconazole for treatment of dermatophyte onychomycosis: a meta-analysis

Terbinafine: An update

Safety and efficacy of new generation azole antifungals in the management of recalcitrant superficial fungal infections and onychomycosis

The safety of oral antifungals for the treatment of onychomycosis

Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial

Terbinafine resistance in dermatophytes: Time to revisit alternate antifungal therapy

Antifungal resistance in dermatophytes – review of the epidemiology, diagnostic challenges and treatment strategies for managing Trichophyton indotineae infections

Treatment of onychomycosis in an era of antifungal resistance: Role for antifungal stewardship and topical antifungal agents

Terbinafine: a pharmacological and clinical review

The Emerging Terbinafine-Resistant Trichophyton Epidemic: What Is the Role of Antifungal Susceptibility Testing?

Clinical and pharmacokinetic investigations of oral terbinafine in patients with tinea unguium

Reliable and rapid identification of terbinafine resistance in dermatophytic nail and skin infections

Antifungal Resistance, Susceptibility Testing and Treatment of Recalcitrant Dermatophytosis Caused by Trichophyton indotineae: A North American Perspective on Management

An update on the myriad antifungal resistance mechanisms in dermatophytes and the place of experimental and existential therapeutic agents for Trichophyton complex implicated in tinea corporis and cruris

A systematic review on the emergence of terbinafine-resistant Trichophyton indotineae in Europe: Time to act?

COMPARATIVE STUDY OF EFFICACY OF ORAL TERBINAFINE ALONE AND ORAL TERBINAFINE WITH TOPICAL 8% CICLOPIROX OLAMINE IN ONYCHOMYCOSIS

Systemic absorption and safety of topical terbinafine hydrochloride 10% solution (MOB015B): a phase 1 maximal usage trial in patients with moderate-to-severe onychomycosis

Antifungal drug susceptibility profile of clinically important dermatophytes and determination of point mutations in terbinafine-resistant isolates

Efficacy and influence on the blood glucose when treated with terbinafine for onychomycosis in patients with diabetes mellitus

Study on Efficacy and Safety of Terbinafine Vs. Itraconazole in the Treatment of Tinea Pedis